Zimmer Biomet acquires CD Diagnostics

Zimmer Biomet recently acquired CD Diagnostics, a Claymont, Del.-based diagnostics company that develops immunoassays and biomarker testing.

Advertisement

Warsaw, Ind.-based Zimmer Biomet and CD Diagnostics first partnered in 2012 to develop and market diagnostics for the musculoskeletal healthcare market.

“We’re excited to team up with CD Diagnostics to accelerate the pace of innovation in musculoskeletal diagnostics, ramp up adoption of testing into standard protocols, and arm surgeons with critical data to inform diagnosis, staging, treatment and recovery,” said Dan Williamson, group president of joint reconstruction for Zimmer Biomet.

Financial terms of the transaction were not disclosed.

More articles on supply chain:

Medline, Community Health Ventures enter group purchasing partnership
FDA approves Boston Scientific’s implantable defibrillator
FDA grants priority review status to muscular dystrophy drug

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.